Headlines Covid-19 Specialties Trending Feeds Videos

A two-center phase I trial published in the New England Journal of Medicine shows safety and feasibility of locally administered oncolytic herpes simplex virus-1...

Mashup Score:18

Cancer Cell

Prolonged TCR-driven stimulation can induce a dysfunctional T cell state, broadly described as T cell exhaustion, limiting the clinical potential of chimeric antigen receptor (CAR) T cells....

Addeo et al. show patients with cancer have poor antibody response after 1 dose and excellent antibody response at 3 weeks after 2 doses...

Addeo et al. show patients with cancer have poor antibody response after 1 dose and excellent antibody response at 3 weeks after 2 doses...

Addeo et al. show patients with cancer have poor antibody response after 1 dose and excellent antibody response at 3 weeks after 2 doses...

Addeo et al. show patients with cancer have poor antibody response after 1 dose and excellent antibody response at 3 weeks after 2 doses...

Addeo et al. show patients with cancer have poor antibody response after 1 dose and excellent antibody response at 3 weeks after 2 doses...

Addeo et al. show patients with cancer have poor antibody response after 1 dose and excellent antibody response at 3 weeks after 2 doses...

Evaluating the IgG levels against SARS-CoV-2 spike protein, Thakkar et al. demonstrate high rates of seroconversion in a diverse cohort of patients with cancer, while...

Immune checkpoint blockade (ICB) is transforming treatment for many cancers. While ICB alone initially demonstrated efficacy in patients with metastatic melanoma, it has expanded...